Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Deucravacitinib in moderate-to-severe psoriasis.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Deucravacitinib in moderate-to-severe psoriasis.
Deucravacitinib in moderate-to-severe psoriasis. Immunotherapy. 2022 Nov; 14(16):1279-1290.
View in:
PubMed
subject areas
Chronic Disease
Double-Blind Method
Humans
Psoriasis
Quality of Life
Treatment Outcome
authors with profiles
Kenneth Gordon